In the afternoon, Innocare (09969) rose more than 4%. As of the time of publication, it rose by 4.18% to HKD 4.74, with a turnover of HKD 15.7857 million.
According to the WiseNews, Innocare (09969) rose over 4% in the afternoon. As of the time of publication, it rose by 4.18% to HKD 4.74, with a turnover of HKD 15.7857 million.
Innocare announced that the China National Medical Products Administration (NMPA) has accepted the biological product license application (BLA) for CD19 monoclonal antibody Tafasitamab in combination with Lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in adults who are not suitable for autologous stem cell transplantation. The application has been included in priority review.
Tafasitamab is an Fc-engineered, humanized monoclonal antibody that targets CD19. Tafasitamab in combination with Lenalidomide has been approved in Hong Kong, the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of relapsed/refractory DLBCL in adults who are not suitable for autologous stem cell transplantation.